Cancer

News

AZ begins liver cancer immunotherapy tie-up with AVEO

AstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in liver cancer.

Views & Analysis

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

AstraZeneca looks to CRISPR to boost success rates

Between 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase III completion were at 4%, below an already-low industry standard of 5%.

News

Closeup of X-ray photography of human brain

Certain brain tumours could respond to immunotherapy

Some brain tumours may respond to immunotherapy after all, according to a new study.

News

Gilead hires Roche's pharma chief Daniel O'Day as CEO

Roche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO at the end of this year, the company has announced.

News

AZ's cancer drug fails again, Roche's rival gets new use

AstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved in the sought-after first line lung cancer indication

News

NICE gives final seal of approval for Gilead's CAR-T in NHL

NICE has finalised its guidance recommending interim NHS funding for Gilead’s Yescarta CAR-T therapy, to treat patients with aggressive forms of non-Hodgkin lymphoma.

AZ begins liver cancer immunotherapy tie-up with AVEO

AstraZeneca looks to CRISPR to boost success rates

Certain brain tumours could respond to immunotherapy

Gilead hires Roche's pharma chief Daniel O'Day as CEO

AZ's cancer drug fails again, Roche's rival gets new use

NICE gives final seal of approval for Gilead's CAR-T in NHL

AI specialists Enveda and Basecamp rake in the cash

Discover a new era of healthcare panel engagement: Grounded ...

Cancer

Editor's Picks